France

12 Vaccines Approved for Use in France

Protein Subunit

Novavax

Nuvaxovid

Approved in 40 countries
22 trials in 14 countries
Approval Source: ema.europa.eu
RNA

Moderna

Spikevax

Approved in 88 countries
70 trials in 24 countries
Approval Source: ema.europa.eu
RNA

Pfizer/BioNTech

Comirnaty

Approved in 149 countries
100 trials in 31 countries
Approval Source: ema.europa.eu
Non Replicating Viral Vector

Janssen (Johnson & Johnson)

Ad26.COV2.S

Approved in 111 countries
23 trials in 23 countries
Approval Source: ema.europa.eu
Non Replicating Viral Vector

Oxford/AstraZeneca

Vaxzevria

Approved in 149 countries
73 trials in 34 countries
Approval Source: ema.europa.eu
RNA

Moderna

Spikevax Bivalent Original/Omicron BA.1

Approved in 38 countries
5 trials in 4 countries
Approval Source: ema.europa.eu
RNA

Pfizer/BioNTech

Comirnaty Bivalent Original/Omicron BA.1

Approved in 35 countries
3 trials in 5 countries
Approval Source: ema.europa.eu
RNA

Pfizer/BioNTech

Comirnaty Bivalent Original/Omicron BA.4/BA.5

Approved in 33 countries
4 trials in 1 country
Approval Source: ema.europa.eu
Non Replicating Viral Vector

Janssen (Johnson & Johnson)

Jcovden

Approved in 113 countries
26 trials in 25 countries
Approval Source: ema.europa.eu
Inactivated

Valneva

VLA2001

Approved in 33 countries
9 trials in 4 countries
Approval Source: ema.europa.eu
RNA

Moderna

Spikevax Bivalent Original/Omicron BA.4/BA.5

Approved in 33 countries
2 trials in 1 country
Approval Source: ema.europa.eu
Protein Subunit

Sanofi/GSK

VidPrevtyn Beta

Approved in 30 countries
3 trials in 2 countries
Approval Source: ema.europa.eu

8 in Clinical Trials in France

Protein Subunit

Sanofi/GSK

Recombinant Protein

6 trials in 7 countries
Protein Subunit

Sanofi/GSK

SP/GSK subunit B.1.351 vaccine

3 trials in 2 countries
Protein Subunit

Sanofi/GSK

SP/GSK subunit D614 vaccine

RNA

Pfizer/BioNTech

Comirnaty

Approved in 149 countries
100 trials in 31 countries
Non Replicating Viral Vector

Janssen (Johnson & Johnson)

Ad26.COV2.S

Approved in 111 countries
23 trials in 23 countries
Non Replicating Viral Vector

ReiThera

GRAd-COV2

5 trials in 12 countries
Non Replicating Viral Vector

Janssen (Johnson & Johnson)

Jcovden

Approved in 113 countries
26 trials in 25 countries
Protein Subunit

Sanofi/GSK

VidPrevtyn Beta

Approved in 30 countries
3 trials in 2 countries

2 Vaccines with Trials in France are No Longer Progressing

RNA

Curevac

CVnCoV

9 trials in 12 countries
Replicating Viral Vector

Institut Pasteur

COVID-19-101